<?xml version="1.0" encoding="UTF-8"?>
<p id="Par65">Since HCQ is an immunomodulatory rather than immunosuppressive drug, and it probably interferes with viral entry, it might have a protective effect for patients treated with HCQ. However, SLE patients should not be considered resistant to COVID-19. Recently, there are increasing reports of COVID-19 patients with SLE [
 <xref ref-type="bibr" rid="CR28">28</xref>, 
 <xref ref-type="bibr" rid="CR30">30</xref>, 
 <xref ref-type="bibr" rid="CR32">32</xref>, 
 <xref ref-type="bibr" rid="CR41">41</xref>]. Mathian et al. have reported the clinical picture of the course of COVID-19 in SLE patients treated with HCQ [
 <xref ref-type="bibr" rid="CR32">32</xref>]. The authors concluded that HCQ does not seem to prevent COVID-19, at least its severe forms, in patients with SLE since most of the SLE patients in this study received long-term treatment with HCQ, having blood concentrations of the drug within the therapeutic range. The findings of Konig et al. were in the same lines, as mentioned above [
 <xref ref-type="bibr" rid="CR41">41</xref>].
</p>
